{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:57:19Z","timestamp":1781143039767,"version":"3.54.1"},"reference-count":25,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,3,31]],"date-time":"2018-03-31T00:00:00Z","timestamp":1522454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cytomegalovirus (<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>) remains an important pathogen in solid organ transplant patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>We executed a hybrid prophylactic and pre\u2010emptive valganciclovir (<jats:styled-content style=\"fixed-case\">VGCV<\/jats:styled-content>) prophylaxis to prevent <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> infection in heart transplant patients with anti\u2010thymocyte globulin (<jats:styled-content style=\"fixed-case\">ATG<\/jats:styled-content>) induction and retrospectively evaluated the efficacy and safety of this regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Hundred adult heart transplant patients between 2004 and 2010 were included. Recipients with <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> serostatus D+\/R\u2212 received <jats:styled-content style=\"fixed-case\">VGCV<\/jats:styled-content> 900\u00a0mg <jats:styled-content style=\"fixed-case\">OD<\/jats:styled-content> for 6 months and 94.2% (81\/86) of R+ recipients received a low\u2010dose 450\u00a0mg <jats:styled-content style=\"fixed-case\">OD<\/jats:styled-content> for 3 months. Blood <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> was monitored until 3 months after cessation of the prophylaxis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All patients accomplished the prophylaxis. The overall incidence of <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> disease was 4% (4\/100) and it was more frequent in D+\/R\u2212 patients (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.001). Three of eighty\u2010six (3.5%) of R+ patients had <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> infection (one <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> disease) while on prophylaxis, 2\/3 were still on the original significantly reduced renal dose though. There was one late <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> disease in both D+\/R\u2212 and R+ groups. Ganciclovir\/<jats:styled-content style=\"fixed-case\">VGCV<\/jats:styled-content> treatment was successful in all patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The hybrid strategy with low\u2010dose <jats:styled-content style=\"fixed-case\">VGCV<\/jats:styled-content> in R+ patients with <jats:styled-content style=\"fixed-case\">ATG<\/jats:styled-content> was efficient and safe. The good treatment results indicate that the regimen did not lead to a clinically relevant resistance. Optimal renal dosage is essential throughout prophylaxis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.12868","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T09:22:36Z","timestamp":1520414556000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Low\u2010dose valganciclovir prohylaxis is efficacious and safe in cytomegalovirus seropositive heart transplant recipients with anti\u2010thymocyte globulin"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5307-9096","authenticated-orcid":false,"given":"Mari","family":"Eriksson","sequence":"first","affiliation":[{"name":"Department of Medicine Division of Infectious Diseases Helsinki University Hospital  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne J.","family":"Jokinen","sequence":"additional","affiliation":[{"name":"Heart and Lung Transplantion Program Heart and Lung Center Helsinki University Hospital  Helsinki Finland"},{"name":"Transplantation Laboratory University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanni","family":"S\u00f6derlund","sequence":"additional","affiliation":[{"name":"Heart and Lung Center Helsinki University Central Hospital and Research Programs\u2032unit Diabetes and Obesity Research Program  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"H\u00e4mm\u00e4inen","sequence":"additional","affiliation":[{"name":"Heart and Lung Transplantion Program Heart and Lung Center Helsinki University Hospital  Helsinki Finland"},{"name":"Transplantation Laboratory University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyri","family":"Lommi","sequence":"additional","affiliation":[{"name":"Heart and Lung Transplantion Program Heart and Lung Center Helsinki University Hospital  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Lemstr\u00f6m","sequence":"additional","affiliation":[{"name":"Heart and Lung Transplantion Program Heart and Lung Center Helsinki University Hospital  Helsinki Finland"},{"name":"Transplantation Laboratory University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,3,31]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12006"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S36578"},{"key":"e_1_2_7_4_1","unstructured":"AlfordCA. CMV in: Fields BN et\u00a0al.;Virology 2nded New York NY1990 1980\u20102010"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2009.00907.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/652438"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.655"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00451.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01207.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1989.03420240075030"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2002.20907.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00735.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.3.468"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02824.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2009.02.009"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.02133.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544050-00003"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000145989.22373.03"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02897.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181ff1493"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1086\/519941"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2005.00112.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31829df29d"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2013.08.023"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12780"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000570"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12868","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T23:29:41Z","timestamp":1695511781000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,31]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1111\/tid.12868"],"URL":"https:\/\/doi.org\/10.1111\/tid.12868","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,31]]},"assertion":[{"value":"2017-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12868"}}